Wall Street brokerages expect ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) to post earnings of ($0.18) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.19) in the same quarter last year, which indicates a positive year over year growth rate of 5.3%. The business is scheduled to announce its next earnings results on Wednesday, December 13th.

On average, analysts expect that ESSA Pharma will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.49). For the next financial year, analysts forecast that the company will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.57). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ESSA Pharma.

EPIX has been the topic of several research analyst reports. Zacks Investment Research raised shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Dawson James reissued a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Finally, Bloom Burton downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.75.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/01/zacks-analysts-anticipate-essa-pharma-inc-epix-to-announce-0-18-eps.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.